Alpha 2.0
Login Register
» Authors » Yusuke Chihara

Yusuke Chihara

Explore the profile of Yusuke Chihara including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 83
Citations 742
Followers 0
Related Specialties
Oncology
General Medicine
Pulmonary Medicine
Top 10 Co-Authors
Koichi Takayama
Tadaaki Yamada
Takayuki Takeda
Shinsuke Shiotsu
Junji Uchino
Masahiro Iwasaku
Nobuyo Tamiya
Yoshiko Kaneko
Kenji Morimoto
Osamu Hiranuma
Published In
Cancers (Basel)
Transl Lung Cancer Res
JTO Clin Res Rep
Oncologist
Target Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, et al.
Lung Cancer . 2025 Feb; 201:108447. PMID: 39970730
Objectives: In patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, a chemoimmunotherapy regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) has shown promising outcomes...
2.
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, et al.
Lung Cancer . 2025 Jan; 200:108104. PMID: 39889466
Background: Clinical trial eligible patients with advanced non-small cell lung cancer (aNSCLC) and low programmed cell death ligand 1 (PD-L1) expression achieve greater benefit from immune checkpoint inhibitor (ICI) combination...
3.
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, et al.
Clin Lung Cancer . 2025 Jan; PMID: 39864962
Background: Although chemoimmunotherapy is recommended for advanced nonsquamous non-small cell lung cancer (NSCLC) with low programmed cell death ligand 1 (PD-L1) expression, no head-to-head comparisons of immune checkpoint inhibitors (ICIs)...
4.
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
Kawachi H, Yamada T, Tamiya M, Negi Y, Kijima T, Goto Y, et al.
Oncoimmunology . 2024 Dec; 14(1):2442116. PMID: 39681395
This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high...
5.
Public assistance and survival equality in patients with EGFR mutation-positive lung cancer
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, et al.
Jpn J Clin Oncol . 2024 Dec; 55(3):228-236. PMID: 39673402
Background: Disparities in public assistance or the urbanization level of a residential region can affect cancer treatment outcomes. This study aimed to investigate whether these factors affect the overall survival...
6.
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with NSCLC with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs Chemoimmunotherapy: A Multicenter, Retrospective Study
Nishioka N, Hata T, Yamada T, Goto Y, Amano A, Negi Y, et al.
Cancer Res Treat . 2024 Nov; PMID: 39482992
Purpose: Thyroid transcription factor 1 (TTF-1) expression is a useful predictor of treatment efficacy in advanced non-squamous non-small-cell lung cancer (NSCLC). This study aimed to evaluate whether TTF-1 could predict...
7.
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01
Hibino M, Imamura Y, Shimoyama R, Fukui T, Fukai R, Iwase A, et al.
Target Oncol . 2024 Sep; 19(6):925-939. PMID: 39302602
Background: Osimertinib shows higher effectiveness than first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in the initial treatment of EGFR-mutated non-small cell lung cancer. However, its superiority in terms...
8.
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study
Kuno H, Nishioka N, Yamada T, Kunimatsu Y, Yoshimura A, Hirai S, et al.
Cancers (Basel) . 2024 Sep; 16(17). PMID: 39272894
Sarcopenia assessed at a single time point is associated with the efficacy of immunotherapy, and we hypothesized that longitudinal changes in muscle mass may also be important. This retrospective study...
9.
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study
Kataoka N, Katayama Y, Yamada T, Morimoto K, Takeda T, Okada A, et al.
Transl Lung Cancer Res . 2024 Sep; 13(8):1929-1937. PMID: 39263030
Background: Tumor markers such as serum carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) are utilized for assessing the effectiveness of chemotherapy in non-small cell lung cancer (NSCLC) patients....
10.
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
Tachibana Y, Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, et al.
Invest New Drugs . 2024 Aug; 42(5):538-546. PMID: 39168900
The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer. Immune checkpoint inhibitor (ICI)-based treatment is globally used as first-line treatment for...